Biofrontera (BFRI) Revenue (2020 - 2026)

Biofrontera has reported Revenue for 7 years, with the latest figure at $12.0 million in Q2 2026.

• On a quarterly basis, Revenue rose 32.92% year-over-year to $12.0 million in Q2 2026; TTM through Jun 2026 was $45.1 million, a 15.14% increase from a year earlier, with the FY2025 full-year figure at $41.7 million, up 11.75% from the prior year.
• Revenue was $12.0 million for Q2 2026 at Biofrontera, down from $17.1 million in the prior quarter.
• The five-year high for Revenue was $17.1 million in Q4 2025, with the low at $4.3 million in Q3 2022.
• Average Revenue over 5 years is $9.0 million, with a median of $8.9 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Revenue dropped 23.88% in 2022, then surged 105.83% in 2023.
• Over 5 years, Revenue stood at $10.1 million in 2022, then rose by 4.46% to $10.6 million in 2023, then grew by 18.53% to $12.6 million in 2024, then surged by 36.16% to $17.1 million in 2025, then slipped by 29.81% to $12.0 million in 2026.
• The last three Revenue figures came in at $12.0 million (Q2 2026), $17.1 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.